Development and psychometric evaluation of the Hypnotic-Use Urge Scale

[1]  B. Saini,et al.  To Drug or Not to Drug: A Qualitative Study of Patients’ Decision-Making Processes for Managing Insomnia , 2018, Behavioral sleep medicine.

[2]  Chien-Ming Yang,et al.  Qualitative Study of Long-Term Sedative-Hypnotic use Patterns , 2016 .

[3]  R. N. Brogden,et al.  Triazolam: A Review of its Pharmacological Properties and Therapeutic Efficacy in Patients with Insomnia , 1981, Drugs.

[4]  H. Aubin,et al.  Craving's place in addiction theory: Contributions of the major models , 2010, Neuroscience & Biobehavioral Reviews.

[5]  S. Pallesen,et al.  Patient characteristics and predictors of sleep medication use , 2010, International clinical psychopharmacology.

[6]  H. Rosenberg,et al.  Clinical and laboratory assessment of the subjective experience of drug craving. , 2009, Clinical psychology review.

[7]  D. Riemann,et al.  The treatments of chronic insomnia: a review of benzodiazepine receptor agonists and psychological and behavioral therapies. , 2009, Sleep Medicine Reviews.

[8]  G. Zammit.  Comparative Tolerability of Newer Agents for Insomnia , 2009, Drug safety.

[9]  M. Sateia,et al.  Clinical guideline for the evaluation and management of chronic insomnia in adults. , 2008, Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine.

[10]  Adam Johnson,et al.  Computing motivation: Incentive salience boosts of drug or appetite states , 2008, Behavioral and Brain Sciences.

[11]  N. Cimolai.  Zopiclone: is it a pharmacologic agent for abuse? , 2007, Canadian family physician Medecin de famille canadien.

[12]  P. Jolliet,et al.  Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. , 2007, British journal of clinical pharmacology.

[13]  A. Krystal,et al.  Nightly treatment of primary insomnia with eszopiclone for six months: effect on sleep, quality of life, and work limitations. , 2007, Sleep.

[14]  B. Vandermeer,et al.  The Efficacy and Safety of Drug Treatments for Chronic Insomnia in Adults: A Meta-analysis of RCTs , 2007, Journal of General Internal Medicine.

[15]  F. Zitman,et al.  Predictors of Long-Term Benzodiazepine Abstinence in Participants of a Randomized Controlled Benzodiazepine Withdrawal Program , 2006, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[16]  C. Morin,et al.  Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinants of help-seeking behaviors. , 2006, Sleep medicine.

[17]  A. Krystal,et al.  An evaluation of the efficacy and safety of eszopiclone over 12 months in patients with chronic primary insomnia. , 2005, Sleep medicine.

[18]  B. Vandermeer,et al.  Manifestations and management of chronic insomnia in adults. , 2005, Evidence report/technology assessment.

[19]  National Institutes of Health State of the Science Conference statement on Manifestations and Management of Chronic Insomnia in Adults, June 13-15, 2005. , 2005, Sleep.

[20]  J. Walsh.  Pharmacologic management of insomnia. , 2004, The Journal of clinical psychiatry.

[21]  Michael Soyka,et al.  Impact of craving on alcohol relapse during, and 12 months following, outpatient treatment. , 2004, Alcohol and alcoholism.

[22]  P. Savard,et al.  Psychological distress and adaptational problems associated with benzodiazepine withdrawal and outcome: a replication. , 2004, Addictive behaviors.

[23]  Daniel J Buysse,et al.  The treatment of chronic insomnia: drug indications, chronic use and abuse liability. Summary of a 2001 New Clinical Drug Evaluation Unit meeting symposium. , 2004, Sleep medicine reviews.

[24]  D. Drover.  Comparative Pharmacokinetics and Pharmacodynamics of Short-Acting Hypnosedatives , 2004, Clinical pharmacokinetics.

[25]  I. Lucki,et al.  Chronic use of benzodiazepines and psychomotor and cognitive test performance , 2004, Psychopharmacology.

[26]  E. Laska,et al.  Sustained efficacy of eszopiclone over 6 months of nightly treatment: results of a randomized, double-blind, placebo-controlled study in adults with chronic insomnia. , 2003, Sleep.

[27]  S. Iliffe,et al.  Older adults and withdrawal from benzodiazepine hypnotics in general practice: effects on cognitive function, sleep, mood and quality of life , 2003, Psychological Medicine.

[28]  F. Zitman,et al.  Development and psychometric evaluation of the Benzodiazepine Craving Questionnaire. , 2003, Addiction.

[29]  C. Shapiro,et al.  Cognitive effects of long‐term benzodiazepine use in older adults , 2003, Human psychopharmacology.

[30]  I. Liappas,et al.  Zolpidem dependence case series: possible neurobiological mechanisms and clinical management , 2003, Journal of psychopharmacology.

[31]  C. Morin,et al.  Validation of the Insomnia Severity Index as an outcome measure for insomnia research. , 2001, Sleep medicine.

[32]  C. Shapiro,et al.  Self‐report of memory and affective dysfunction in association with medication use in a sample of individuals with chronic sleep disturbance , 2000, Human psychopharmacology.

[33]  D. Kripke.  Chronic hypnotic use: deadly risks, doubtful benefit. REVIEW ARTICLE. , 2000, Sleep medicine reviews.

[34]  A. Holbrook,et al.  Meta-analysis of benzodiazepine use in the treatment of insomnia. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[35]  S. Tiffany.  Cognitive Concepts of Craving , 1999, Alcohol research & health : the journal of the National Institute on Alcohol Abuse and Alcoholism.

[36]  T. Einarson,et al.  Assessment of the risk of therapeutic dose benzodiazepine withdrawal reactions using meta-analysis , 1998 .

[37]  D. Sheehan,et al.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. , 1998, The Journal of clinical psychiatry.

[38]  S. Fortmann,et al.  Craving is associated with smoking relapse: findings from three prospective studies. , 1997, Experimental and clinical psychopharmacology.

[39]  G. Dunbar,et al.  The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDI , 1997, European Psychiatry.

[40]  G. Dunbar,et al.  The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability , 1997, European Psychiatry.

[41]  M. Ohayon,et al.  Epidemiological study on insomnia in the general population. , 1996, Sleep.

[42]  M. Mahowald,et al.  Long-term, nightly benzodiazepine treatment of injurious parasomnias and other disorders of disrupted nocturnal sleep in 170 adults. , 1996, The American journal of medicine.

[43]  K. Berridge,et al.  The neural basis of drug craving: An incentive-sensitization theory of addiction , 1993, Brain Research Reviews.

[44]  Charles M. Morin,et al.  Insomnia: Psychological Assessment and Management , 1993 .

[45]  P. Morselli,et al.  The Safety and Efficacy of Zolpidem in Insomniac Patients: A Long-Term Open Study in General Practice , 1992, The Journal of international medical research.

[46]  S. Tiffany,et al.  The development and initial validation of a questionnaire on smoking urges. , 1991, British journal of addiction.

[47]  L. Johnson,et al.  Rebound Insomnia: A Critical Review , 1989, Journal of clinical psychopharmacology.

[48]  J. Mendels,et al.  Efficacy Without Tolerance or Rebound Insomnia for Midazolam and Temazepam After Use for One to Three Months , 1987, Journal of clinical pharmacology.

[49]  T. Roth,et al.  Dose determinants of rebound insomnia. , 1986, British journal of clinical pharmacology.

[50]  I. Oswald,et al.  Benzodiazepine hypnotics remain effective for 24 weeks. , 1982, British medical journal.